Literature DB >> 12707577

The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets.

Thomas Dörner1, Gerd R Burmester.   

Abstract

Our understanding of the role of B cells as part of the immune system has been remarkably expanded in the past few years. Autoimmunity, the production of autoantibodies or the activation and expansion of autoimmune T cells, is relatively common, whereas the development of autoimmune diseases with destruction of tissue is much less frequent. In rheumatoid arthritis, the autoantigen(s) involved in tissue damage and their role in disease have not been fully elucidated. Recent data suggest that the impact of B cells in rheumatoid arthritis may be of significance; therefore, a depleting anti-B cell therapy appears to be another therapeutic strategy. This review will focus on recent findings of the role of B cells in rheumatoid arthritis and the implications to target B cells in this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707577     DOI: 10.1097/00002281-200305000-00011

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  48 in total

Review 1.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

3.  The impact of Rituximab therapy on the chromosomes of patients with Rheumatoid arthritis.

Authors:  Sekib Sokolović; Sida Kasumagić; Mirela Mackić-Durović; Izeta Aganović-Musinović
Journal:  Bosn J Basic Med Sci       Date:  2010-05       Impact factor: 3.363

4.  Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.

Authors:  Abby Jones Weldon; Ioana Moldovan; Marven G Cabling; Elvin A Hernandez; Sheri Hsu; Jennifer Gonzalez; Andrea Parra; Abigail Benitez; Nasim Daoud; Keith Colburn; Kimberly J Payne
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

Review 5.  B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Authors:  Jennifer Kwan-Morley; Daniel Albert
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

6.  The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab.

Authors:  B Mayrbaeurl; M Hinterreiter; S Burgstaller; M Windpessl; J Thaler
Journal:  Clin Rheumatol       Date:  2007-07-10       Impact factor: 2.980

7.  Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.

Authors:  Achille Aouba; Christian Pagnoux; Boris Bienvenu; Alfred Mahr; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-12       Impact factor: 8.667

Review 8.  The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

Review 9.  Emerging cell and cytokine targets in rheumatoid arthritis.

Authors:  Gerd R Burmester; Eugen Feist; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

Review 10.  [Translational aspects on the role of B-cells in autoimmune diseases. "From bench to bedside" and "from bed to benchside"].

Authors:  H Mei; T Dörner
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.